Skip to main content

VOR

Stock

VOR

Stock
Health Care
Biotechnology

Performance overview

VOR Price
Price Chart

Forward-looking statistics

Beta
1.05
Risk
100.00%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VOR33.

Company info

SectorHealth Care
IndustryBiotechnology
Employees163
Market cap$83.6M

Fundamentals

Enterprise value$173.2M
Revenue$0.0
Revenue per employee—
Profit margin0.00%
Debt to equity46.59

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$1.51
Dividend per share—
Revenue per share—
Avg trading volume (30 day)$62M
Avg trading volume (10 day)$180M
Put-call ratio—

Macro factor sensitivity

Growth-5.4
Credit+9.7
Liquidity-1.7
Inflation-6.1
Commodities-3.4
Interest Rates-0.2

Valuation

Dividend yield0.00%
PEG Ratio-1.62
Price to sales—
P/E Ratio-1.62
Enterprise Value to Revenue—
Price to book3.61

Upcoming events

Next earnings dayMay 15, 2025
Next dividend day—
Ex. dividend day—

News

Vor Biopharma's RemeGen Deal Paves Way For Multi-Billion Dollar Autoimmune Market

H.C. Wainwright upgraded Vor Biopharma Inc. VOR, highlighting the company's 'rebirth' following the in-licensing of telitacicept.

Benzinga (June 30, 2025)
Vor Bio Stock Skyrockets 250% in the Past Week: Here's Why

The VOR stock soars in the past week after a licensing deal with RemeGen. The company also appoints a chief executive officer and chairman.

Zacks Investment Research (June 30, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free